Anchiano Therapeutics Ltd (NASDAQ:ANCN) and Evofem Biosciences Inc. (NASDAQ:EVFM), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings and Valuation

In table 1 we can see Anchiano Therapeutics Ltd and Evofem Biosciences Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Anchiano Therapeutics Ltd and Evofem Biosciences Inc.

Analyst Recommendations

Anchiano Therapeutics Ltd and Evofem Biosciences Inc. Ratings and Recommendations are available in the next table.

Anchiano Therapeutics Ltd has a 214.61% upside potential and an average price target of $14.

Institutional & Insider Ownership

The shares of both Anchiano Therapeutics Ltd and Evofem Biosciences Inc. are owned by institutional investors at 0.75% and 60.9% respectively. Insiders owned roughly 23.87% of Anchiano Therapeutics Ltd’s shares. On the other hand, insiders owned about 21.6% of Evofem Biosciences Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Anchiano Therapeutics Ltd has -47.66% weaker performance while Evofem Biosciences Inc. has 22.2% stronger performance.

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.